[Federal Register Volume 62, Number 33 (Wednesday, February 19, 1997)]
[Notices]
[Pages 7468-7469]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-3956]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration


Center for Substance Abuse Prevention; Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given of the 
meeting of the Drug Testing Advisory Board of the Center for Substance 
Abuse Prevention in April 1997.
    The Drug Testing Advisory Board (DTAB) is having a 3-day scientific 
meeting to discuss drug testing alternative specimens and technologies 
as they apply to workplace drug testing programs. The entire meeting is 
open to the public; however, attendance by the public will be limited 
to space available. The first two days will consist of presentations on 
the principles and criteria of workplace drug testing program 
requirements and industry representatives discussing alternative 
specimens/technologies (urine, hair, saliva, sweat, and non-instrument 
based on-site tests). The presentations will be focused on the 
following areas for each alternative specimen/technology: specimen 
collection and chain of custody, initial test reagents and procedures, 
confirmatory test procedures, internal quality control program, 
reporting test results, interpreting test results, and an external 
quality assurance program. On the third day, the DTAB will review the 
presentations, identify areas of concern, and make recommendations 
concerning those specimens/technologies for workplace drug testing.
    Interested persons may present information or views, orally or in 
writing, on these issues pending before the Board. Those desiring to 
make formal presentations should notify the contact person before March 
7. A coordinator for each alternative specimen/technology will select 
the presenters. The presenters who will discuss the underlying 
principles and

[[Page 7469]]

criteria for each major topic are required to submit their 
presentations in writing at least four weeks before the meeting. These 
will be shared with all presenters at least 3 weeks before the meeting. 
The presenters describing how each type of specimen and/or technology 
satisfies, or does not satisfy, the requirements (each presentation is 
limited to 15 minutes) are required to submit their presentations in 
written form at least two weeks before the meeting. These will be 
shared with all presenters.
    An agenda for this meeting and a roster of board members may be 
obtained from: Ms. Giselle Hersh, Division of Workplace Programs, Room 
13A-54, 5600 Fishers Lane, Rockville, MD 20857, Telephone: (301) 443-
6014.
    Substantive program information may be obtained from the contact 
whose name and telephone number is listed below.

    Committee Name: Drug Testing Advisory Board.
    Meeting Date: April 28-30, 1997.
    Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, 
Maryland 20852.
    Open: April 28-30, 1997, 8:30 a.m.-5:00 p.m.
    Contact: Donna M. Bush, Ph.D.; Executive Secretary, Telephone: 
(301) 443-6014 and FAX: (301) 443-3031.

    Dated: February 12, 1997.
Jeri Lipov,
Committee Management Officer, SAMHSA.
[FR Doc. 97-3956 Filed 2-18-97; 8:45 am]
BILLING CODE 4162-20-P